Lenz Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Lenz Therapeutics registers the resale of 1,578,947 shares of common stock issued in a July 2024 private placement, following its merger with Graphite Bio.
NASDAQ
S-1/A: LENZ Therapeutics Files Amendment to S-1 Registration for Resale of Common Stock After Merger
LENZ Therapeutics files an amendment to its S-1 registration statement, covering the resale of 1,297,411 shares of common stock issued in a PIPE financing following its recent merger with Graphite Bio.
NASDAQ
Lenz Therapeutics registers for the resale of 1,297,411 shares of common stock issued in a PIPE financing following its merger with Graphite Bio.